在心力衰竭中使用-葡萄糖共运输体2抑制剂:现实世界的研究
Luis Fernando Valladales-Restrepo1,2,3, Daniela Torrente-López3, Carlos Manuel Bedoya-Toro3
1Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira-Audifarma S.A, Pereira, Colombia.
Expert review of cardiovascular therapy
|November 30, 2025
概括
在哥伦比亚的心力衰竭患者中,-葡萄糖共传输体-2 抑制剂 (SGLT2i) 越来越多地被使用,显示出良好的坚持和持久性. SGLT2i治疗减少了住院病例,特别是在具有高并发症的人群中.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 现实世界的证据.
背景情况:
- 心力衰竭 (HF) 管理正在随着新的治疗选择而发展.
- -葡萄糖共载体-2抑制剂 (SGLT2i) 已证明在高血压中具有益处,无论糖尿病状况如何.
- 了解不同人群中SGLT2i的使用模式至关重要.
研究的目的:
- 评估SGLT2i在哥伦比亚心力衰竭患者的实际使用情况.
- 分析SGLT2i治疗一年的指示,坚持和持续性.
- 评估SGLT2i对住院率的影响.
主要方法:
- 对500名用SGLT2i治疗的心力衰竭患者的回顾性分析.
- 对药物模式,坚持和持续性的评估.
- 描述性和多变量分析以确定影响结果的因素.
主要成果:
- SGLT2i 主要用于心力衰竭与减少喷射率 (HFrEF) 和NYHA类II/III.
- 一年后观察到的高度坚持 (80.9%) 和持续性 (71.8%).
- 在SGLT2i治疗期间,住院病例显著减少 (12.2%vs24.4%).
- 较高的并发症负担 (查尔森并发症指数≥3) 与持续性增加有关.
结论:
- SGLT2i主要为具有显著并发症的HFrEF患者开处方.
- 在这个群体中,SGLT2i在现实世界中的坚持和持续是有利的.
- 在心力衰竭患者中,SGLT2i疗法与住院减少有关.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
01:30Heart Failure V: Medical Management
195
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
195
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:22Heart Failure Drugs: Diuretics
763
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
763
01:29Heart Failure II: Pathophysiology
658
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
658
01:22Heart Failure Drugs: β-Blockers
724
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
724